Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 8/20 | 0.39 |
| ▸ | DRD2 | P14416 | 7/20 | 0.39 |
| ▸ | DRD3 | P35462 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656270 | 0.83 | GRIN1 (0.60) | GRIN1GRIN2BKCNH2SMN1; SMN2DRD4 | |
| SCHEMBL8008822 | 0.83 | GRIN1 (0.72) | GRIN1GRIN2BKCNH2SMN1; SMN2DRD4 | |
| SCHEMBL13656111 | 0.80 | GRIN1 (0.67) | GRIN1GRIN2BKCNH2ALDH1A1 | |
| SCHEMBL2017364 | 0.78 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2SMN1; SMN2DRD4 | |
| SCHEMBL13656132 | 0.76 | GRIN1 (0.67) | GRIN1GRIN2BALDH1A1KDM4ELMNA | |
| SCHEMBL13656307 | 0.74 | GRIN1 (0.50) | GRIN1GRIN2BKCNH2DRD4DRD2 | |
| SCHEMBL13656204 | 0.73 | GRIN1 (0.64) | GRIN1GRIN2BKCNH2SMN1; SMN2LMNA | |
| SCHEMBL13656210 | 0.71 | KMT2A (0.56) | GRIN1GRIN2BKCNH2ALDH1A1KDM4E | |
| SCHEMBL13656203 | 0.69 | GRIN1 (0.71) | GRIN1GRIN2BALDH1A1 | |
| SCHEMBL9594625 | 0.68 | GRIN1 (0.51) | GRIN1GRIN2BKCNH2SMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885KCNH2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.